Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
Chronic kidney disease (CKD) is a major public health concern around the world. It is a significant risk factor for cardiovascular disease (CVD), and, as it progresses, the risk of cardiovascular events increases. Furthermore, end-stage kidney disease severely affects life expectancy and quality of...
Saved in:
Main Authors: | Kisho Miyasako, Yujiro Maeoka, Takao Masaki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/1/53 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01) -
Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression
by: I-Wen Chen, et al.
Published: (2025-02-01) -
Role of Metformin in Preventing New-Onset Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus
by: Yu-Ling Lin, et al.
Published: (2025-01-01) -
Characterization of diabetic kidney disease in 235 patients: clinical and pathological insights with or without concurrent non-diabetic kidney disease
by: Mengjie Jiang, et al.
Published: (2025-01-01) -
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
by: Katharine Barnard-Kelly, et al.
Published: (2025-02-01)